Patents by Inventor Mikkel Andersen

Mikkel Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LRRK2 inhibitors
    Patent number: 11993612
    Abstract: The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: May 28, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Jensen, Mikkel Jessing, Wanwan Yu, David Rodriguez Diaz, Jacob Nielsen, Christopher Richard Jones, Thomas Andersen, Mikkel Fog Jacobsen
  • Leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Patent number: 11958865
    Abstract: The present invention is directed to compounds of formula IIa These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: April 16, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Jensen, Thomas Andersen, Mikkel Jessing, Jacob Nielsen, Henrik Daver, Christopher Richard Jones
  • Trimeric binding proteins for trimeric cytokines
    Publication number: 20070010658
    Abstract: The present invention pertains to the provision of trimeric binding units which bind to trimeric cytokines. In particular there is provided a trimeric polypeptide comprising a trimerising domain and three monomers with binding members capable of binding a trimeric cytokine. Preferably, the trimeric binding units bind in a manner such that upon binding, all receptor binding sites of the trimeric cytokine are substantially blocked, and hence the potential biological activity of the trimeric cytokine is suppressed. In one aspect the invention relates to trimeric binders capable of binding to trimeric cytokines of the Tumor necrosis factor ligand superfamily, such as TNF, TRAIL, RANKL, TWEAK, APRIL and BAFF.
    Type: Application
    Filed: October 29, 2003
    Publication date: January 11, 2007
    Inventors: Thor Holtet, Mikkel Andersen, Helle Ottow